Rxo (RXO) Revenue (2021 - 2026)

Rxo (RXO) has reported Revenue for 6 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.

• Revenue for Q1 2026 came in at $1.4 billion, down 0.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 13.1% YoY), and the FY2025 annual result was $5.7 billion, up 26.2% from the prior year.
• Revenue was $1.4 billion for Q1 2026 at Rxo, down from $1.5 billion in the prior quarter.
• Over five years, Revenue peaked at $1.7 billion in Q4 2024 and troughed at $913.0 million in Q1 2024.
• Average Revenue over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2022.
• Year-over-year, Revenue decreased 23.02% in 2023 and soared 70.45% in 2024.
• Over 5 years, Revenue stood at $1.1 billion in 2022, then dropped by 12.68% to $978.0 million in 2023, then jumped by 70.45% to $1.7 billion in 2024, then decreased by 11.88% to $1.5 billion in 2025, then dropped by 3.0% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Revenue figures were $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.